BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 28031235)

  • 1. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis.
    Mazzio EA; Li N; Bauer D; Mendonca P; Taka E; Darb M; Thomas L; Williams H; Soliman KF
    BMC Complement Altern Med; 2016 Nov; 16(1):467. PubMed ID: 27846826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
    Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
    Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
    Mazzio EA; Soliman KFA
    Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
    El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
    Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells.
    Majumdar G; Adris P; Bhargava N; Chen H; Raghow R
    BMC Genomics; 2012 Dec; 13():709. PubMed ID: 23249388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
    Shi Y; Jia Y; Zhao W; Zhou L; Xie X; Tong Z
    Int J Mol Med; 2018 Jul; 42(1):435-442. PubMed ID: 29620153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
    Qiu X; Rong X; Yang J; Lu Y
    BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
    Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
    Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
    Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W
    BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B.
    Liu N; Zhao LJ; Li XP; Wang JL; Chai GL; Wei LH
    Chin Med J (Engl); 2012 Sep; 125(18):3273-8. PubMed ID: 22964322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A.
    Gialitakis M; Kretsovali A; Spilianakis C; Kravariti L; Mages J; Hoffmann R; Hatzopoulos AK; Papamatheakis J
    Nucleic Acids Res; 2006; 34(3):765-72. PubMed ID: 16452299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
    Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
    Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
    Hao ZF; Su YM; Wang CM; Yang RY
    Tumour Biol; 2015 Mar; 36(3):1471-6. PubMed ID: 25371069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.